Part D Drug Pricing Change Would Affect Commercial Plans, PBMs Say
Executive Summary
The Pharmaceutical Care Management Association is arguing that CMS' plan to redefine the allowable cost for drugs will have a negative impact not only on Medicare Part D prescription plans, but on commercial plans as wellYou may also be interested in...
Medicare Rule Brings More Drug Price Transparency To Part D
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: